Nucleic acid therapies involving DNA or RNA have significant potential to treat genetic disorders, infectious diseases, and cancer; however, research suggests that less than 1% of injected nucleic acid doses reach target cells in an active form. An article in WIRES Nanomedicine and Nanobiotechnology highlights two of the major barriers to this therapeutic strategy, and how they might be overcome.
Delivery to the target cell and transport to the sub-cellular compartment where the nucleic acids are therapeutically active represent the most significant challenges to address. The authors explore how nanoparticle delivery systems can be modified with targeting molecules to increase accumulation in specific cells, and how the composition of the nanoparticle can be engineered to manipulate or disrupt cellular membranes and facilitate delivery to the optimal sub-cellular compartments.
“Controlling the sub-cellular delivery of DNA and RNA is the next major frontier for biotherapeutics. If we can overcome these barriers, DNA and RNA technology has the potential to revolutionize the treatment of a range of diseases,” said corresponding author Angus P.R. Johnston, PhD, of Monash University, in Australia.
URL upon publication: https://onlinelibrary.wiley.com/doi/10.1002/wnan.1809
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Nanotechnology is universally recognized as one of the most important scientific fields of the twenty-first century. The advancement of this field relies on the combined efforts of researchers from many different backgrounds, including clinicians, biomedical engineers, materials scientists, applied physicists, and toxicologists. The need for a high-quality interdisciplinary review forum was pressing, and WIREs Nanomedicine and Nanobiotechnology looks to fill that niche. The topical coverage includes: Toxicology and regulatory issues; Implantable materials and surgical technologies; Diagnostic tools; Nanotechnology approaches to biology; Therapeutic approaches and drug discovery; Biology-inspired nanomaterials.
About Wiley
Wiley is one of the world’s largest publishers and a global leader in scientific research and career-connected education. Founded in 1807, Wiley enables discovery, powers education, and shapes workforces. Through its industry-leading content, digital platforms, and knowledge networks, the company delivers on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.